Leveraging efficient S-CHOICE CLD platform to optimize protein expression

Monday, April 15, 2024 3:00 PM to 3:20 PM · 20 min. (US/Pacific)

CMC & Developability, sponsored by Croda Pharma

Presentation

Room 4

Information

Biologics development organizations are faced with challenges to accelerate the biologics development process, speed up the development timeline to clinic. Optimal Cell Line Development (CLD) process is a key technology driver in drug development programs. Samsung Biologics’s S-CHOice technology platform provides streamlined workflow solutions to tackle heavy CLD workflow limitations while improving manufacturing cost, efficiency and quality.

Samsung Biologics205Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a wide range of bioreactor scales to serve varying client needs and meet growing market demand. We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and have announced plans to construct a fifth plant, which will be operational in April 2025.

Leveraging efficient S-CHOICE CLD platform to optimize protein expression

Information

Log in